CT 023
Alternative Names: CT-023Latest Information Update: 06 Sep 2023
At a glance
- Originator Synkangda Life
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 31 Jul 2023 CT 023 is available for licensing as of 31 Jul 2023. https://www-xkdbio-com.translate.goog/yjxm?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc&_x_tr_sch=http#31
- 31 Jul 2023 Preclinical trials in Diffuse large B cell lymphoma in China (Parenteral), prior to July 2023 (Synkangda life pipeline, July 2023)